US Bancorp DE Acquires 17,523 Shares of Kura Oncology, Inc. (NASDAQ:KURA)

US Bancorp DE boosted its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 79.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,627 shares of the company’s stock after acquiring an additional 17,523 shares during the period. US Bancorp DE’s holdings in Kura Oncology were worth $262,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Virtus ETF Advisers LLC grew its holdings in Kura Oncology by 71.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock worth $64,000 after acquiring an additional 3,061 shares in the last quarter. Pallas Capital Advisors LLC bought a new position in Kura Oncology during the 1st quarter worth about $66,000. Corton Capital Inc. bought a new position in Kura Oncology during the 4th quarter worth about $99,000. Flower City Capital bought a new position in Kura Oncology during the 1st quarter worth about $79,000. Finally, Ameriprise Financial Inc. bought a new position in Kura Oncology during the 4th quarter worth about $130,000.

Analyst Ratings Changes

KURA has been the topic of several recent research reports. Mizuho dropped their target price on shares of Kura Oncology from $32.00 to $30.00 and set an “outperform” rating on the stock in a report on Monday, May 19th. Wall Street Zen cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. Barclays lowered their price target on shares of Kura Oncology from $32.00 to $11.00 and set an “overweight” rating on the stock in a report on Friday, May 2nd. Wedbush restated an “outperform” rating and issued a $36.00 price target on shares of Kura Oncology in a report on Friday, June 20th. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Kura Oncology in a report on Monday, April 28th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $24.10.

Kura Oncology Stock Up 1.7%

KURA stock opened at $6.60 on Friday. The firm has a 50 day moving average of $6.19 and a 200 day moving average of $6.65. The stock has a market capitalization of $572.88 million, a PE ratio of -2.92 and a beta of 0.41. The company has a quick ratio of 6.16, a current ratio of 6.16 and a debt-to-equity ratio of 0.02. Kura Oncology, Inc. has a 52 week low of $5.41 and a 52 week high of $21.57.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Thursday, August 7th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.90). The company had revenue of $15.29 million for the quarter, compared to the consensus estimate of $64.95 million. Sell-side analysts forecast that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.